Size-switchable polymer-based nanomedicines in the advanced
therapy of rheumatoid arthritis

J 2023

Size-switchable polymer-based nanomedicines in the advanced therapy of rheumatoid arthritis

LIBÁNSKÁ, A.; E. RANDÁROVÁ; Svitlana SKOROPLYAS; M. BARTOŠ; J. LUŇÁČKOVÁ et al.

Základní údaje

Originální název

Size-switchable polymer-based nanomedicines in the advanced therapy of rheumatoid arthritis

Autoři

LIBÁNSKÁ, A.; E. RANDÁROVÁ; Svitlana SKOROPLYAS; M. BARTOŠ; J. LUŇÁČKOVÁ; F. LAGER; G. RENAULT; D. SCHERMAN a T. ETRYCH

Vydání

Journal of Controlled Release, Elsevier Science BV, 2023, 0168-3659

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

10404 Polymer science

Stát vydavatele

Nizozemské království

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 10.500

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14310/23:00130761

Organizační jednotka

Přírodovědecká fakulta

Klíčová slova anglicky

Polymer conjugate; Drug delivery; Inflammation; HPMA; Dexamethasone; Collagen II -induced arthritis; Passive targeting

Štítky

14314010, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 11. 5. 2023 16:00, Mgr. Marie Novosadová Šípková, DiS.

Anotace

V originále

Chronic inflammatory diseases such as rheumatoid arthritis represent a substantial socio-economic impact and have a high prevalence in the modern world. Nano-sized polymer therapeutics have shown suitable characteristics for becoming the next generation of anti-inflammatory nanomedicines. Here, we present biocompatible and stimuli-sensitive N-(2-hydroxypropyl)methacrylamide based polymer conjugates with the anti-inflammatory drug dexamethasone (DEX), which has been tailored for prolonged blood circulation, enhanced inflammatory site accumulation, site-specific drug release and subsequent elimination of the carrier via urine excretion. The hydrodynamic size of novel polymer-DEX nanomedicine was adjusted to prolong its blood circulation whilst maintaining the renal excretability of the polymer carrier after drug release in inflamed tissue. The therapeutic efficacy of the studied polymer nanomedicines was evaluated in a model of dissipated chronic arthritis, i.e. collagen II-induced arthritis, in mice. The pH-sensitive drug attachment enabled enhanced blood circulation with minimal systemic drug release, as well as rapid drug activation in affected joints. Importantly, unlike free DEX, the polymer nanomedicines were able to diminish joint inflammation and arthritis-induced bone damage - even at a reduced dosing regimen - as evaluated by micro computed tomography (micro-CT).

Citovat

LIBÁNSKÁ, A.; E. RANDÁROVÁ; Svitlana SKOROPLYAS; M. BARTOŠ; J. LUŇÁČKOVÁ; F. LAGER; G. RENAULT; D. SCHERMAN a T. ETRYCH. Size-switchable polymer-based nanomedicines in the advanced therapy of rheumatoid arthritis. Journal of Controlled Release. Elsevier Science BV, 2023, roč. 353, January, s. 30-41. ISSN 0168-3659. Dostupné z: https://doi.org/10.1016/j.jconrel.2022.11.027.

@article{2281801,
   author = {Libánská, A. and Randárová, E. and Skoroplyas, Svitlana and Bartoš, M. and Luňáčková, J. and Lager, F. and Renault, G. and Scherman, D. and Etrych, T.},
   article_number = {January},
   doi = {https://doi.org/10.1016/j.jconrel.2022.11.027},
   keywords = {Polymer conjugate; Drug delivery; Inflammation; HPMA; Dexamethasone; Collagen II -induced arthritis; Passive targeting},
   language = {eng},
   issn = {0168-3659},
   journal = {Journal of Controlled Release},
   title = {Size-switchable polymer-based nanomedicines in the advanced therapy of rheumatoid arthritis},
   url = {https://doi.org/10.1016/j.jconrel.2022.11.027},
   volume = {353},
   year = {2023}
}

TY  - JOUR
ID  - 2281801
AU  - Libánská, A. - Randárová, E. - Skoroplyas, Svitlana - Bartoš, M. - Luňáčková, J. - Lager, F. - Renault, G. - Scherman, D. - Etrych, T.
PY  - 2023
TI  - Size-switchable polymer-based nanomedicines in the advanced therapy of rheumatoid arthritis
JF  - Journal of Controlled Release
VL  - 353
IS  - January
SP  - 30-41
EP  - 30-41
PB  - Elsevier Science BV
SN  - 01683659
KW  - Polymer conjugate
KW  - Drug delivery
KW  - Inflammation
KW  - HPMA
KW  - Dexamethasone
KW  - Collagen II -induced arthritis
KW  - Passive targeting
UR  - https://doi.org/10.1016/j.jconrel.2022.11.027
N2  - Chronic inflammatory diseases such as rheumatoid arthritis represent a substantial socio-economic impact and have a high prevalence in the modern world. Nano-sized polymer therapeutics have shown suitable characteristics for becoming the next generation of anti-inflammatory nanomedicines. Here, we present biocompatible and stimuli-sensitive N-(2-hydroxypropyl)methacrylamide based polymer conjugates with the anti-inflammatory drug dexamethasone (DEX), which has been tailored for prolonged blood circulation, enhanced inflammatory site accumulation, site-specific drug release and subsequent elimination of the carrier via urine excretion. The hydrodynamic size of novel polymer-DEX nanomedicine was adjusted to prolong its blood circulation whilst maintaining the renal excretability of the polymer carrier after drug release in inflamed tissue. The therapeutic efficacy of the studied polymer nanomedicines was evaluated in a model of dissipated chronic arthritis, i.e. collagen II-induced arthritis, in mice. The pH-sensitive drug attachment enabled enhanced blood circulation with minimal systemic drug release, as well as rapid drug activation in affected joints. Importantly, unlike free DEX, the polymer nanomedicines were able to diminish joint inflammation and arthritis-induced bone damage - even at a reduced dosing regimen - as evaluated by micro computed tomography (micro-CT).
ER  -

LIBÁNSKÁ, A.; E. RANDÁROVÁ; Svitlana SKOROPLYAS; M. BARTOŠ; J. LUŇÁČKOVÁ; F. LAGER; G. RENAULT; D. SCHERMAN a T. ETRYCH. Size-switchable polymer-based nanomedicines in the advanced therapy of rheumatoid arthritis. \textit{Journal of Controlled Release}. Elsevier Science BV, 2023, roč.~353, January, s.~30-41. ISSN~0168-3659. Dostupné z: https://doi.org/10.1016/j.jconrel.2022.11.027.

Přehled o publikaci